{"filing":{"accession_number":"0001171843-26-004991","cik":"0001898416","ticker":"ALVOW","company_name":"Alvotech","form":"6-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"f6k_072926.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1898416/000117184326004991/f6k_072926.htm"},"events":[{"id":21506,"run_id":19397,"accession_number":"0001171843-26-004991","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The press release announces the successful closure of an FDA inspection of Alvotech's manufacturing facility in Reykjavik with a \"Voluntary Action Indicated\" (VAI) classification. This is a regulatory milestone affecting the company's ability to manufacture and advance its biosimilar pipeline toward FDA approval. While not a discrete event type like exec_appointment or debt_issuance, it is a material operational and regulatory development that would affect a reasonable investor's assessment of the company's manufacturing compliance and regulatory progress, particularly given the company's focus on biosimilar development and the importance of FDA manufacturing inspections to product approvals.","company_name":"Alvotech","ticker":"ALVOW","filing_date":"2026-07-29","form":"6-K","submitted_at":null,"items":[{"id":21160,"accession_number":"0001171843-26-004991","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The press release announces the successful closure of an FDA inspection of Alvotech's manufacturing facility in Reykjavik with a \"Voluntary Action Indicated\" (VAI) classification. This is a regulatory milestone affecting the company's ability to manufacture and advance its biosimilar pipeline toward FDA approval. While not a discrete event type like exec_appointment or debt_issuance, it is a material operational and regulatory development that would affect a reasonable investor's assessment of the company's manufacturing compliance and regulatory progress, particularly given the company's focus on biosimilar development and the importance of FDA manufacturing inspections to product approvals.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T15:00:49.679389+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21160,"accession_number":"0001171843-26-004991","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The press release announces the successful closure of an FDA inspection of Alvotech's manufacturing facility in Reykjavik with a \"Voluntary Action Indicated\" (VAI) classification. This is a regulatory milestone affecting the company's ability to manufacture and advance its biosimilar pipeline toward FDA approval. While not a discrete event type like exec_appointment or debt_issuance, it is a material operational and regulatory development that would affect a reasonable investor's assessment of the company's manufacturing compliance and regulatory progress, particularly given the company's focus on biosimilar development and the importance of FDA manufacturing inspections to product approvals.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T15:00:49.679389+00:00","company_name":"Alvotech","ticker":"ALVOW","filing_date":"2026-07-29"}]}